ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M

ImmunityBio, Inc.

2025-Q2 EPS reported -$0.26 revenue$42,942,000

Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.
Net loss $92.6M ($0.10/share) vs $134.6M in Q2 2024; operating loss narrowed.
Cash $153.7M at June 30; $80M equity financing closed July 2025 with potential $96M warrant proceeds.
UK MHRA approved ANKTIVA for BCG-unresponsive NMIBC; FDA refused to file sBLA for papillary-only NMIBC, company re-evaluating.
ANKTIVA unit volume grew 246% in 1H 2025 vs 2H 2024 since J-code approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.